Travere Therapeutics' Cash from Investing Activities rose 87.73% to $86.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year decrease of 67.53%. This contributed to the annual value of $99.3 million for FY2024, which is 165.51% up from last year.
Per Travere Therapeutics' latest filing, its Cash from Investing Activities stood at $86.6 million for Q3 2025, which was up 1,685.38% from $4.8 million recorded in Q2 2025.
Travere Therapeutics' 5-year Cash from Investing Activities high stood at $104.9 million for Q1 2024, and its period low was -$105.7 million during Q1 2021.
Its 3-year average for Cash from Investing Activities is $7.3 million, with a median of $4.8 million in 2025.
Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 822.85% in 2023, then skyrocketed by 383.21% in 2024.
Travere Therapeutics' Cash from Investing Activities (Quarterly) stood at $7.4 million in 2021, then crashed by 597.98% to -$36.7 million in 2022, then surged by 50.47% to -$18.2 million in 2023, then crashed by 341.79% to -$80.3 million in 2024, then skyrocketed by 87.73% to $86.6 million in 2025.
Its last three reported values are $86.6 million in Q3 2025, $4.8 million for Q2 2025, and $41.3 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value